Side-by-side comparison of AI visibility scores, market position, and capabilities
FY2025 (ended Mar 31, 2025): JPY 21.6887T (+6.2%) | Operating Profit: JPY 1.2134T (-12.2%) | FY2024: JPY 20.4286T (+20.8%) | Q3 FY2024 (9 months): Op Profit JPY 1.1399T, margin 7.0% | Auto sales down 297k (Asia impact) | FY2026 guidance: Net profit JPY 250B (-70.1%), Revenue JPY 20.3T (-6.4%)
Honda Motor Co., Ltd. is a Japanese multinational mobility conglomerate founded in 1948 by Soichiro Honda and Takeo Fujisawa in Hamamatsu, Japan. Starting as a motorcycle manufacturer, Honda expanded into automobiles, power equipment, marine engines, and aerospace, becoming one of the largest and most diversified mobility companies in the world. With over 90 million vehicles sold globally and a reputation built on engineering reliability, fuel efficiency, and innovation, Honda operates manufacturing facilities across more than 30 countries on six continents.\n\nHonda's automotive lineup ranges from mass-market sedans and SUVs — including the best-selling Civic and CR-V — to trucks, minivans, and the premium Acura brand. The company is executing a major pivot to electrification through the Honda 0 Series, a new EV architecture designed from the ground up for battery-electric vehicles launching in 2026. Honda's partnership with General Motors on battery technology, combined with its investment in solid-state battery development, reflects a multi-path electrification strategy designed to hedge technology risk while building scale.\n\nHonda reported FY2025 revenue of JPY 21.7 trillion, a 6.2% year-over-year increase, driven by strong North American demand and favorable currency tailwinds. The company faces intensifying competition from Chinese EV manufacturers in Asia and is exploring a potential merger with Nissan as part of broader Japanese automotive consolidation. Honda's engineering culture, global manufacturing scale, and brand credibility in reliability position it as a resilient and well-capitalized incumbent navigating the EV transition.
FY2024 Revenue: $372.8B (+4.2% YoY) | Net income: $4.6B (down from $8.4B) | Operating income: $8.5B (-38% YoY) | Q4 2024: $97.7B | Healthcare benefits segment challenged
CVS Health Corporation is one of the largest healthcare companies in the United States, formed through a series of major acquisitions that transformed CVS Pharmacy — a retail drugstore chain founded in Lowell, Massachusetts in 1963 — into a vertically integrated healthcare enterprise. Key acquisitions include Caremark Rx (pharmacy benefit management, 2007), Aetna (health insurance, $69 billion, 2018), and Oak Street Health (primary care clinics, 2023). CVS Health's model positions the company as a healthcare touchpoint spanning insurance enrollment, prescription management, and clinical care delivery.\n\nCVS Health's segments include Health Care Benefits (Aetna insurance for employer groups, Medicare, and Medicaid), Health Services (Caremark PBM, specialty pharmacy, infusion), and Pharmacy & Consumer Wellness (retail operations). CVS operates 9,000+ pharmacy locations and is expanding MinuteClinic and HealthHUB formats that co-locate clinical services with pharmacy for primary and chronic care management. The company also operates pharmacy-only conversion locations removing front-end retail to concentrate on health services.\n\nCVS Health reported FY2024 revenue of $372.8 billion (+4.2% YoY) with net income of approximately $4.6 billion. Near-term pressure on Aetna's Medicare Advantage business — elevated medical cost ratios from post-pandemic care utilization — has driven benefit redesigns and market exits. Despite these headwinds, CVS Health's vertically integrated model combining PBM leverage, insurance membership, and retail pharmacy access represents a structurally unique healthcare asset at scale.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.